|
Indian Pediatr 2009;46: 785-790 |
|
Long Chain Polyunsaturated
Fatty Acids and Immunity in Infants |
Sridhar Ganapathy
From the Department of Pediatrics, Lion
Tarachand Bapa Hospital, Sion, Mumbai, India.
Correspondence to: Dr Sridhar Ganapathy, 14-276,
Tata Co-op Building, Road 31, Sion (East), Mumbai
400 022, India. Email:
[email protected]
|
Abstract
An infant is usually born
with a deficient immune system, and the long
chain polyunsaturated fatty acids (LC-PUFA) in
breast milk plays an important role in the
development and maturation of infant’s immune
system. This article reviews the role of LC-PUFA
in breast milk in the development of immunity
and prevention of atopic manifestations in
infants. The review also attempts to assess the
correct proportion of these nutrients that needs
to be present in infant formulae for babies in
whom breast milk is unavailable and formula milk
is unavoidable. It was concluded that LC-PUFA
plays a vital role in overall development of
immunity in the infant. Clinicians should ensure
that LC-PUFA are supplied to the term and
preterm infant in the form of breastmilk or
provided in right proportions in formula, if
breast milk is unavailable.
Keywords: Immunity, Infants Nutrition,
Polyunsaturated fatty acids.
|
The immune system in
human body is developed to protect the individual
from pathogens. It has highly complex pathways for
recognition of these "invaders" in order to
eliminate them. Immunity of a person develops as he
progresses from a neonate with an immature immune
system to a mature immunocompetent adult and finally
to a decline of host defenses with ageing. Breast
milk offers many essential nutrients important for
the development of the infant’s immune system. There
are four important components in infant diet that
aid in development of immunity: nucleotides,
glutamine, arginine and essential fatty acids.
Omega-3 and omega-6 fatty acids are essential fatty
acids i.e. those not synthesized by the body
and need to be supplemented in diet. These form an
important component of the human milk and have a
significant role in the overall growth and
development of the infant.
Essential Fatty Acids,
Polyunsaturated Fatty Acids and LC-PUFA
Depending on their degree of
saturation, fatty acids are classified as either
saturated fatty acids, monounsaturated fatty acids,
or polyunsaturated fatty acids (PUFA). PUFA are
those that contain more than one double bond, and
include omega-3, omega-6, omega-9, conjugate fatty
acids and other polyunsaturates. The essential fatty
acids (EFA) are all omega-3 (n-3) and omega-6
(n-6) methylene-interrupted fatty acids.
Alpha Linolenic acid (ALA) is the principal Omega-3
fatty acid, which a healthy human can convert into
eicosapentaenoic acid (EPA), and later into
docosahexaenoic acid (DHA). Linoleic acid is the
primary Omega-6 fatty acid. A healthy human with
good nutrition will convert linoleic acid into gamma
linolenic acid (GLA), which will later be
synthesized, with EPA from the Omega-3 group, into
eicosanoids. Arachidonic acid (AA) is an omega-6
PUFA and is a precursor in the production of
eicosanoids. Linoleic acid is commonly found in
plant oils (safflower, sunflower oil etc.)
whereas alpha linolenic acid is found in flaxseed,
soyabean etc. Long chain n-3 PUFA: EPA and
DHA are either synthesized in human body from ALA or
directly obtained in diet from marine fish oils.
PUFA are found in high concentration (16.6%) in
breast milk(1). The arachidonic acid content in
breast milk is mostly constant, averaging about
0.45% of total fatty acid content. DHA level varies
(0.1%–3.8%) with the diet of the mother. Human milk
also contains low amounts of some other PUFA, such
as
a-linolenic
acid (18:3 n-6, GLA), dihomo-a
-linolenic
acid (20:3 n-6, DGLA) and docosapentaenoic
acid (22:5 n-3 or 22:5 n-6 DPA)(2).
Breast milk also contains lipases which aid in
better fat absorption and utilization.
Immunity in Newborns and Role of
Nutrition
A neonate is born with naïve and
immature immune system, a state that is often termed
as ‘physiological immunodeficiency’. This
encompasses all arms of the host immune system and
is reflected in their increased susceptibility to
infections, often with severe consequences. The
infant has a gastrointestinal tract (GIT) lacking
microflora, with undeveloped mucosal defenses. The
innate immunity is mostly lacking in neonates and
initially so is the humoral immunity, and the
neonate is almost wholly dependent on the passively
acquired maternal IgG and IgA antibodies. Maternal
IgG is transported actively across the placenta to
the fetus particularly in the last trimester, and
IgA is passed on to the baby via breast milk(3).
However, these passively acquired antibodies are
incapable of mounting a cell mediated response
rendering the neonate susceptible to various
pathogens(4). Not just quantitative, there are also
qualitative differences in the IgG and IgA produced
by infants in response to pathogens(3).
T cells are important components
of the cell mediated immunity with T-helper cells
being important for the adaptive immunity. T cell
function differs in neonates from adults in the
respect that the former have fewer antigen-specific
T-cell precursors than adults(5). It is also seen
that neonates and children produce less of the T
cell mediated interleukins like IL-2, IL-4, IL-6 and
IL-10(6-8). There is a dominance of T helper cells
and regulatory T cell effector responses in both
mother and fetus during pregnancy. This helps in
prevention of rejection of the immunologically
different fetus by the maternal immune system(9).
This T-helper dominance in neonates is usually down
regulated soon after birth and inability to do so
leads to development of allergic propensity.
During and soon after birth, the
development of the neonatal immunity begins. The
exposure to pathogens in the environment as well as
the immunological factors provided in the breast
milk make the foundations of development of an
independent immune system in the infant. This
immunity includes both systemic immunity like cell
mediated and humoral, and gut associated immune
systems from the gut associated lymphoid tissue
(GALT) in the infant(10).
Nutrition in infants provides
essential factors for development and growth in
general, and also for development and maturation of
the immune system. It helps develop the
gastrointestinal microflora with subsequent
benefits. On the other hand, introduction of
nutrients in early life also provides the infant
with food-derived antigens that his immune system
must recognize so that these nutrients in turn may
modify or modulate immune maturation and responses.
These mechanisms have been cited as reasons why
nutrition in infancy may affect strength and
maturity of the immune system, tolerance to ‘self’
and benign environmental antigens, and development
of immune mediated and autoimmune disorders(9).
Breast Milk and its Effect on
Infant Immunity
Apart from various nutrients, the
human milk also provides various protective agents
to help boost the immunity of the feeding infant (Box
I)(10). Human neonates are able to
synthesize small amounts of LC-PUFA (AA and DHA)
from precursor fatty acids such as linolenic acid
and alpha linolenic acid(11). However, the rate of
synthesis may be insufficient to allow normal or
optimal LC-PUFA accretion in body tissues. Thus it
is important that the infant is provided these
essential fatty acids in diet for optimum growth and
development(2).
Box I Immune-boosting Properties of Breastmilk |
1. For the acquired immune
system
a. IgA and other
immunoglobulins (Humoral)
b. Neutrophils and
lymphocytes (Cell mediated)
2. For the innate immune system
a. Multifunctional
milk components like fatty acids, lactoferrin
and lactalbumin
b. Glycans
c. Immunomodulatory
agents like cytokines, nucleic acids,
soluble cytokine receptors, and antioxidants. |
In comparison to human milk,
cow’s milk triglycerides contain a higher proportion
of short chain fatty acids and a lower proportion of
long chain and polyunsaturated fatty acids(12). In
cases of adopted or abandoned infants or in cases
where mother’s milk is not available for the baby,
cow’s milk substitution does not provide the
essential balance and quality of fatty acids. Thus
the formula that is offered to babies in these cases
should be fortified with the right quality and
quantity of LA, ALA, AA, DHA and other LC-PUFA.
Role of LC-PUFA in the Infant
Long chain polyunsaturated fatty
acids (LC-PUFA) are important for both structure and
function in the neonate. Their structural role
includes formation of the brain and the meninges
since they form an important component of
phospholipids(13). Phospholipids form an important
component of cell membranes of the body and are also
a part of the inflammatory precursor cells and
mature cells. Thus, phospholipids form an important
building block in the development of the infant’s
immune system. During neonatal life, there is a
rapid accretion of AA and DHA in infant brain, DHA
in retina, and of AA in the whole body. Essential
fatty acids thus form an important part in the
neurodevelopmental maturation and development of the
visual functions(2). LC-PUFA also function as
precursors of eicosanoids which play a role in the
prostaglandin pathways. Prostaglandins, thromboxanes
and leukotrienes play an important role in cellular
functions, inflammation and regulation of cellular
immunity(14).
Benefits to the immune system
There is compelling evidence that
n-3 PUFA especially EPA and DHA have an impact on
various functions of the immune system. LC-PUFA
plays a role in host resistance to infection and
other disorders of the immune system. Various
mechanisms have been proposed to explain the role of
these fatty acids as immunomodulators. LC-PUFA
assists in lymphocyte proliferation and activation,
macrophage function, natural killer cell function,
and neutrophil function. These actions are mainly
mediated by modulation of the eicosanoid pathways
and lipid peroxidation pathways(15). The fatty acid
composition of inflammatory and immune cells changes
according to the dietary fatty acid composition(14).
The n-6 PUFA, especially
arachidonic acid, play an important role in immunity
as the precursors of prostaglandins and leukotrienes.
However, an n-3 PUFA, EPA, is also a
substrate for cycloxygenase and lipoxygenase and
replaces other mediators of inflammation from the
arachidonic acid pathways. This results in decreased
monocyte and neutrophil chemotaxis and production of
proinflammatory cytokines. Modulation of the
prostaglandin synthesis pathways also affects the
regional blood flow. An optimum ratio between plasma
concentration of n-3 and n-6 PUFA thus
needs to be maintained to ensure a normally
functional immune system. Benefits have been noted
in autoimmune disorders with supplementation of n-3
PUFA in diet. This is mainly due to their
substitution in the arachidonic acid metabolism
pathways that lead to inflammation(13). This shows
that LC-PUFA has immunomodulatory as well as
anti-inflammatory activity in humans.
Effects of maternal LC-PUFA
administration during pregnancy and lactation on
neonates
LC-PUFA is vital in development
of the fetal nervous system and immune system during
pregnancy. There is usually a decline in maternal
plasma contents of n-3 PUFA especially in the early
postpartum period. A DHA supplementation in diet may
be helpful here. It has also been found that there
is considerable placental transfer of LC-PUFA,
enabling better growth in infants of pregnancies
supplemented with LC-PUFA. Supplementation of
pregnant mothers with LC-PUFA also improves birth
size of the infant as well as reduces incidence of
preterm birth(16). Such additions to diet during
pregnancy and lactation have also proved to be
beneficial in later cognitive development of the
baby. Dietary supplementation of LC-PUFA, both to
pregnant and lactating mothers and to neonates has
shown evidence of improved immunity among
infants(17).
Benefits to the low birth weight
baby
About 80% of intrauterine DHA and
AA accumulation occurs during the last 3 months of
pregnancy, the period when the fetus develops
adipose tissue and extensive brain growth. Preterm
birth interrupts this availability of DHA and AA for
synthesis of structural lipids. Therefore, preterm
infants are particularly disadvantaged with respect
to access to AA and DHA needed for brain maturation
and other developmental processes compared with term
infants. During neonatal life, preterm infants also
have a higher rate of growth; therefore, LC-PUFA
needs are greater than in term infants(2). DHA
deficiency in infants can lead to various
complications like thrombocytopenia, dermatitis,
lack of adequate growth, and most importantly makes
the infant susceptible to various infections. DHA
deficiency can manifest in preterm infants within 72
hours of birth(18).
Observational studies have shown
that immune status among preterm and also in small
for gestational age (SGA) full term neonates in
India is poorer than full term babies making these
special populations of infants more prone to
infections(19). In low birth weight infant, breast
milk is advocated after suitable supplementations
since it provides essential nutritional benefits
such as proteins, amino acids and fatty acids.
Reduction in the rates of neonatal infection and
necrotizing enterocolitis has also been noted with
breastfeeding in such infants(20). However, when
breast milk is unavailable, development of deficient
immunity has been documented in preterm infants on
artificial feeds(21). It has also been documented
that such immune factor deficiency is correctable by
LC-PUFA supplementation(21). There was a rise in
levels of the immune markers among preterm neonates
who were breastfed or who were fed with LC-PUFA
supplemented formulas in comparison to those who
were fed with formulas not having LC-PUFA. Another
study in healthy infants (9-12 months) showed faster
immune maturation when diet was supplemented with
fish oils(22).
LC- PUFA Supplementation in Diet
and Atopy
Infants of atopic mothers have a
high risk of developing allergic phenotypes. Atopy
in infants usually manifests as atopic dermatitis,
allergic rhinitis or asthma. Cord blood estimation
of CD34 + cells
is usually used as a marker to detect such
propensity in neonates. Dietary LC-PUFA has been
shown to reduce allergic tendencies besides
significant immunomodulatory roles. In a double
blind placebo controlled trial, it was found that
mothers who were given LC-PUFA supplementation
during pregnancy and lactation delivered babies with
higher CD34+ cells and also when these infants were
exposed to allergens, they did not show atopic
tendencies. Levels and functions of various other
immune mediators have also found to be altered
favorably in such infants to decrease the risk of
atopy(23).
Altered n-3 and n-6
ratio is noted in the mature milk of atopic mothers.
They have an increased n-6 series of fatty
acids and a lower level of n-3 PUFA that is
sometimes linked to development of atopy among their
breastfed babies. However, it is to be noted that
colostrum of both atopic and non-atopic mothers is
similar in fatty acid compositions. In mothers with
mature breast milk having disturbed fatty acid
ratios, it has been observed that infants are more
prone to atopic sensitization later in life(24).
This finding has been seen in both atopic and non-atopic
mothers. Thus, there appears to be a link between
low n-3 PUFA and disturbed fatty acid balance
in breast milk and risk of atopy in infants. Dietary
LC-PUFA might play an important role in protecting
the infant from development of atopic diseases.
Concerns with LC-PUFA Usage
LC-PUFA supplementation may cause
the formula to become unstable because of ALA
related lipid peroxidation and rancification.
Appropriate balance of linoleic acid and ALA (linoleic
to ALA 5-15 to 1) is recommended to improve
stability of the formula as well as provide benefits
to the infant. Addition of LC-PUFA in the right
proportions to infant formula so that adequate
availability to the infant is ensured also needs to
be judged in terms of cost effectiveness. Most LC-PUFA
containing formulas are more expensive in comparison
to the usual formulas. However, increased demand and
better techniques may take care of this problem in
future.
Recommendations and Conclusions
Supplementation with LC-PUFA in
mothers beyond 22 weeks of gestation and during
lactation is beneficial in development of the immune
system of the infant and reduction in risk of atopic
sensitization. It is also beneficial for the
cognitive and visual development of the infant. In
infants supplemented with dietary fatty acids,
similar benefits are noted. Preterm babies,
especially, need these essential nutrients more than
term babies. Breast milk is rich in the essential
fatty acids, including LC-PUFA, needed for the
optimum growth and development of the infant.
However, when breast milk is not available due to
maternal death or abandonment of infant, it is
recommended that the formula offered to the baby is
fortified with these fatty acids. LC-PUFA present in
breast milk and formula that is supplemented with
LC-PUFA prevents essential fatty acid deficiency and
promotes protein accretion(25).
The IEG (International Expert
Group) recommendations suggest that the addition of
DHA should not exceed 0.5% of total fat intake, and
AA concentration should be at least the same as DHA.
The content of EPA in infant formula should not
exceed the DHA content. As per these recommendations
for ideal formula feed, the total fat content should
be 4.4-6 g/100 kcal and linoleic acid 0.3-1.2 g/100
kcal, alpha linoleic acid 50 mg/100 kcal, and ratio
of linoleic to alpha linoleic acid 5:1-15:1(26).
To conclude, it can be said that
early nutrition in the infant plays an important
role in the overall growth and development of the
immune system, especially if it includes essential
fatty acids. When a term or preterm infant is breast
fed, she is provided with all the nutritional
benefits as breast milk contains all the vital
nutrients required for physical and mental
development, and immunity of the child. All efforts,
therefore, should be made to ensure breastfeeding in
young infants, and mothers should be helped in the
process by appropriate counseling. However, when
breast milk is not available and formula is
unavoidable, supplementation with LC-PUFA with right
mix of fats, carbohydrates and proteins should be
ensured.
Funding: Complete Medical
Group India, for Fast-track Publication.
Competing interest: None
stated.
References
1. Koletzko B, Mrotzek M, Eng B,
Bremer HJ. Fatty acid composition of human milk in
Germany. Am J Clin Nutr 1988; 47: 954-959.
2. Fleith M, Clandinin MT.
Dietary PUFA for preterm and term infants: review of
clinical studies. Crit Rev Food Sci Nutr 2005; 45:
205-229.
3. Janeway C Jr, Travers P,
Walport M, Capra JD. Immunobiology: The Immune
System in Health and Disease, 4 th
ed. London: Taylor & Francis Inc; 1999.
4. Wara DW, Barrett DJ.
Cell-mediated immunity in the newborn: clinical
aspects. Pediatrics 1979; 64: 822-828.
5. Hassan J, Reen DJ. Reduced
primary antigen-specific T-cell precursor
frequencies in neonates is associated with deficient
interleukin-2 production. Immunology 1996; 87:
604-608.
6. Chheda S, Palkowetz KH,
Garofalo R, Rassin DK, Goldman AS. Decreased
interleukin-10 production by neonatal monocytes and
T cells: Relationship to decreased production and
expression of tumor necrosis factor-alpha and its
receptors. Pediatr Res 1996; 40: 475-483.
7. Lewis DB, Prickett KS, Larsen
A, Grabstein K, Weaver M, Wilson CB. Restricted
production of interleukin 4 by activated human T
cells. Proc Natl Acad Sci USA 2005; 85: 9743-9747.
8. Lilic D, Cant AJ, Abinun M,
Calvert JE, Spickett GP. Cytokine production differs
in children and adults. Pediatr Res 1997; 42:
237-240.
9. Calder PC, Krauss-Etschmann S,
de Jong EC, Dupont C, Frick JS, Frokiaer H,
et al. Early nutrition
and immunity: progress and perspectives. Br J Nutr
2006; 96: 774-790.
10. Newburg DS. Innate immunity
and human milk. J Nutr 2005; 135: 1308-1312.
11. Heird WC. The role of
polyunsaturated fatty acids in term and preterm
infants and breastfeeding mothers. Pediatr Clin
North Am 2001; 48: 173-188.
12. Prentice A. Regional
variations in the composition of human milk. In:
Jensens RG, editor. Handbook of Milk Composition.
New York: Academic Press; 1995. p. 115-221.
13. Calder PC. Polyunsaturated
fatty acids, inflammation, and immunity. Lipids
2001; 36: 1007-1024.
14. Neonate and Infant Nutrition
and Immunity. Available from: URL: http://www.
arkinternational.co.uk/Infant%20nutrition.pdf.
Accessed April 21, 2009.
15. Field CJ, Johnson IR, Schley
PD. Nutrients and their role in host resistance to
infection. J Leukoc Biol 2002; 71:16-32.
16. Koletzko B, Larqué E,
Demmelmair H. Placental transfer of long-chain
polyunsaturated fatty acids (LC-PUFA). J Perinat Med
2007; 35 (Suppl 1): S5-S11.
17. Helland IB, Saugstad OD,
Smith L, Saarem K, Solvoll K, Ganes T, et al.
Similar effects on infants of n-3 and n-6 fatty
acids supplementation to pregnant and lactating
women. Pediatrics 2001; 108: 1-10.
18. Foote KD, Mckinnon MJ, Innis
SM. Effect of early introduction of formula vs
fat-free parenteral nutrition on essential fatty
acid status of preterm infants. Am J Clin Nutr 1991;
54: 93-97.
19. Chatrath R, Saili A, Jain M,
Dutta AK. Immune Status of full-term
small-for-gestational age neonates in India. J Trop
Pediatr 1997; 43: 345-348.
20. Schanler RJ. Suitability of
human milk for the low birthweight infant. Clin
Perinatol 1995; 22: 207-222.
21. Field CJ, Thomson CA, Aerde
JEV, Parrott A, Euler A, Lien E, et al. Lower
proportion of CD45RO +
cell and deficient Interleukin-10
production by formula fed infants, compared with
human-fed, is corrected with supplementation of
long-chain polyunsaturated fatty acids. J Pediatr
Gastroenterol Nutr 2000; 31: 291-299.
22. Damsgaard CT, Lauritzen L,
Kjær TMR, Holm PMI, Fruekilde MB, Michaelsen KF,
et al. Fish oil supplementation modulates immune
function in healthy infants. J Nutr 2007; 137:
1031-1036.
23. Denburg JA, Hatfield HM,
Cyr MM, Hayes L, Holt PG, Sehmi R, et al.
Fish oil supplementation in pregnancy modifies
neonatal progenitors at birth in infants at risk of
atopy. Pediatr Res 2005; 57: 276-281.
24. Duchén K, Yu G, Björkstén B.
Atopic sensitization during the first year of life
in relation to long chain polyunsaturated fatty acid
levels in human milk. Pediatr Res 1998: 44: 478-484.
25. Liet JM, Piloquet H, Marchini
JS, Maugère P, Bobin C, Rozé JC, et al.
Leucine metabolism in preterm infants receiving
parenteral nutrition with medium-chain compared with
long-chain triacylglycerol emulsions. Am J Clin Nutr
1999; 69: 539-543.
26. Koletzko B, Baker S, Cleghorn
G, Neto UF, Gopalan S, Hernell O, et al.
Global standard for the composition of infant
formula: Recommendations of an ESPGHAN coordinated
International Expert Group. J Pediatr Gastroenterol
Nutr 2005; 41: 584-599.
|
|
|
|